share_log

Merit Medical Systems Analyst Ratings

Benzinga ·  Aug 16, 2023 22:23
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/16/2023 38.67% Barrington Research → $95 Reiterates Outperform → Outperform
07/26/2023 40.13% Needham → $96 Reiterates Buy → Buy
07/21/2023 34.29% Piper Sandler $85 → $92 Maintains Overweight
07/06/2023 38.67% Barrington Research → $95 Reiterates Outperform → Outperform
06/09/2023 38.67% Barrington Research $90 → $95 Maintains Outperform
06/09/2023 40.13% Needham $90 → $96 Maintains Buy
05/08/2023 35.75% Raymond James $88 → $93 Maintains Outperform
04/27/2023 24.07% Piper Sandler $77 → $85 Maintains Overweight
04/27/2023 31.37% Barrington Research $78 → $90 Maintains Outperform
04/27/2023 18.23% Wells Fargo $74 → $81 Maintains Equal-Weight
04/27/2023 28.45% Raymond James $86 → $88 Maintains Outperform
04/27/2023 31.37% Needham $84 → $90 Maintains Buy
04/18/2023 22.61% Needham $78 → $84 Maintains Buy
04/17/2023 25.53% Raymond James $80 → $86 Maintains Outperform
04/12/2023 13.85% Barrington Research → $78 Reiterates → Outperform
02/23/2023 13.85% Barrington Research → $78 Reiterates → Outperform
02/23/2023 12.39% Piper Sandler $73 → $77 Maintains Overweight
02/23/2023 16.77% Raymond James $72 → $80 Maintains Outperform
02/23/2023 13.85% Needham $73 → $78 Maintains Buy
12/20/2022 5.09% Canaccord Genuity → $72 Downgrades Buy → Hold
10/27/2022 5.09% Raymond James $71 → $72 Maintains Outperform
10/14/2022 -8.04% Canaccord Genuity $69 → $63 Maintains Buy
09/02/2022 0.72% Canaccord Genuity $67 → $69 Maintains Buy
07/28/2022 3.63% Raymond James $72 → $71 Maintains Outperform
02/25/2022 5.09% Raymond James $73 → $72 Maintains Outperform
02/25/2022 6.55% Needham $83 → $73 Maintains Buy
10/29/2021 8.01% Wells Fargo $68 → $74 Maintains Equal-Weight
07/30/2021 6.55% Raymond James $69 → $73 Maintains Outperform
07/30/2021 -0.74% Wells Fargo $65 → $68 Maintains Equal-Weight
07/30/2021 21.15% Needham $73 → $83 Maintains Buy
04/30/2021 6.55% Needham $68 → $73 Maintains Buy
04/30/2021 0.72% Raymond James $61 → $69 Maintains Outperform
02/25/2021 -10.96% Raymond James $60 → $61 Maintains Outperform
02/25/2021 -0.74% Needham $65 → $68 Maintains Buy
01/05/2021 -5.12% Needham → $65 Upgrades Hold → Buy
11/11/2020 -12.42% Raymond James $57 → $60 Maintains Outperform
10/29/2020 5.09% Sidoti & Co. $63 → $72 Maintains Buy
10/29/2020 -25.56% Wells Fargo $42 → $51 Maintains Equal-Weight
10/29/2020 -9.5% Piper Sandler $55 → $62 Maintains Overweight
10/29/2020 -16.8% Raymond James $51 → $57 Maintains Outperform
10/29/2020 -19.72% Canaccord Genuity $51 → $55 Maintains Buy
09/28/2020 -38.7% Wells Fargo → $42 Upgrades Underweight → Equal-Weight
07/30/2020 -19.72% Piper Sandler $50 → $55 Maintains Overweight
07/30/2020 -27.02% Oppenheimer $46 → $50 Maintains Outperform
07/30/2020 -25.56% Raymond James $49 → $51 Maintains Outperform
06/01/2020 -8.04% Sidoti & Co. $55 → $63 Maintains Buy
05/27/2020 -28.48% Raymond James $46 → $49 Maintains Outperform
04/24/2020 -32.86% Raymond James $44 → $46 Maintains Outperform
04/24/2020 -45.99% Wells Fargo $33 → $37 Maintains Underweight
02/25/2020 -27.02% Piper Sandler $42 → $50 Reiterates → Overweight
02/25/2020 -51.83% Wells Fargo $26 → $33 Maintains Underweight
02/25/2020 -31.4% Raymond James $43 → $47 Maintains Outperform
02/03/2020 -37.24% Raymond James → $43 Upgrades Market Perform → Outperform
12/12/2019 — Wells Fargo Downgrades Equal-Weight → Underweight
10/31/2019 -56.21% Piper Sandler $40 → $30 Maintains Overweight
10/31/2019 -19.72% Sidoti & Co. $74 → $55 Maintains Buy
10/31/2019 -56.21% B of A Securities $37 → $30 Maintains Underperform
09/24/2019 -41.61% Oppenheimer → $40 Initiates Coverage On → Outperform
09/20/2019 -45.99% Canaccord Genuity $53 → $37 Maintains Buy
09/17/2019 -41.61% Piper Sandler $58 → $40 Maintains Overweight
09/10/2019 — Raymond James Downgrades Outperform → Market Perform
07/26/2019 — Needham Downgrades Buy → Hold
07/26/2019 -22.64% Canaccord Genuity $63 → $53 Maintains Buy
07/26/2019 — Wells Fargo Downgrades Outperform → Market Perform
10/26/2018 5.09% Canaccord Genuity $70 → $72 Maintains Buy

What is the target price for Merit Medical Systems (MMSI)?

The latest price target for Merit Medical Systems (NASDAQ: MMSI) was reported by Barrington Research on August 16, 2023. The analyst firm set a price target for $95.00 expecting MMSI to rise to within 12 months (a possible 38.67% upside). 23 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Merit Medical Systems (MMSI)?

The latest analyst rating for Merit Medical Systems (NASDAQ: MMSI) was provided by Barrington Research, and Merit Medical Systems reiterated their outperform rating.

When is the next analyst rating going to be posted or updated for Merit Medical Systems (MMSI)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Merit Medical Systems, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Merit Medical Systems was filed on August 16, 2023 so you should expect the next rating to be made available sometime around August 16, 2024.

Is the Analyst Rating Merit Medical Systems (MMSI) correct?

While ratings are subjective and will change, the latest Merit Medical Systems (MMSI) rating was a reiterated with a price target of $0.00 to $95.00. The current price Merit Medical Systems (MMSI) is trading at is $68.51, which is within the analyst's predicted range.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment